CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells

被引:63
作者
Cerutti, A
Schaffer, A
Shah, S
Zan, H
Liou, HC
Goodwin, RG
Casali, P [1 ]
机构
[1] Cornell Univ, Coll Med, Dept Pathol, Div Mol Immunol, New York, NY 10021 USA
[2] Cornell Univ, Grad Sch Med Sci, Program Immunol, New York, NY 10021 USA
[3] Cornell Univ, Coll Med, Dept Med, Div Immunol, New York, NY 10021 USA
[4] Immunex Corp, Seattle, WA 98101 USA
关键词
D O I
10.1016/S1074-7613(00)80607-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We used our monoclonal model of germinal center maturation, CL-01 B cells, to investigate the role of CD30 in human B cell differentiation. CL-01 cells are IgM(+)IgD(+)CD30(+) and switch to IgG, IgA, and IgE when exposed to CD40L and IL-4. Switching is hampered by CD30 coengagement, possibly through interference with the CD40-mediated NF-kappa B-dependent transcriptional activation of downstream C-H genes. The physiological relevance of this phenomenon is emphasized by similar CD30-mediated effects in naive B cells. Expression of CD30 by these cells is induced by CD40L but is inhibited by B cell receptor coengagement and/or exposure to IL-6 and IL-12. Our data suggest that CD30 critically regulates the CD40-mediated differentiation of non-antigen-selected human B cells.
引用
收藏
页码:247 / 256
页数:10
相关论文
共 46 条
  • [1] RETRACTED: Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation (Retracted article. See vol 94, pg 12732, 1997)
    Ansieau, S
    Scheffrahn, I
    Mosialos, G
    Brand, H
    Duyster, J
    Kaye, K
    Harada, J
    Dougall, B
    Hubinger, G
    Kieff, E
    Herrmann, F
    Leutz, A
    Gruss, HJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) : 14053 - 14058
  • [2] IDENTIFICATION OF A SOURCE OF BIOLOGICALLY-ACTIVE CD40 LIGAND
    ARMITAGE, RJ
    SATO, TA
    MACDUFF, BM
    CLIFFORD, KN
    ALPERT, AR
    SMITH, CA
    FANSLOW, WC
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (08) : 2071 - 2076
  • [3] THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME
    ARUFFO, A
    FARRINGTON, M
    HOLLENBAUGH, D
    LI, X
    MILATOVICH, A
    NONOYAMA, S
    BAJORATH, J
    GROSMAIRE, LS
    STENKAMP, R
    NEUBAUER, M
    ROBERTS, RL
    NOELLE, RJ
    LEDBETTER, JA
    FRANCKE, U
    OCHS, HD
    [J]. CELL, 1993, 72 (02) : 291 - 300
  • [4] Cerutti A, 1998, J IMMUNOL, V160, P2145
  • [5] Choe JS, 1996, J IMMUNOL, V157, P1006
  • [6] HOW B-CELLS AND T-CELLS TALK TO EACH OTHER
    CLARK, EA
    LEDBETTER, JA
    [J]. NATURE, 1994, 367 (6462) : 425 - 428
  • [7] CD30-MEDIATED SIGNALING PROMOTES THE DEVELOPMENT OF HUMAN T-HELPER TYPE 2-LIKE T-CELLS
    DELPRETE, G
    DECARLI, M
    DELIOS, MM
    DANIEL, KC
    ALMERIGOGNA, F
    ALDERSON, M
    SMITH, CA
    THOMAS, E
    ROMAGNANI, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) : 1655 - 1661
  • [8] CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival
    Duckett, CS
    Thompson, CB
    [J]. GENES & DEVELOPMENT, 1997, 11 (21) : 2810 - 2821
  • [9] MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE
    DURKOP, H
    LATZA, U
    HUMMEL, M
    EITELBACH, F
    SEED, B
    STEIN, H
    [J]. CELL, 1992, 68 (03) : 421 - 427
  • [10] A new protein containing an SH2 domain that inhibits JAK kinases
    Endo, TA
    Masuhara, M
    Yokouchi, M
    Suzuki, R
    Sakamoto, H
    Mitsui, K
    Matsumoto, A
    Tanimura, S
    Ohtsubo, M
    Misawa, H
    Miyazaki, T
    Leonor, N
    Taniguchi, T
    Fujita, T
    Kanakura, Y
    Komiya, S
    Yoshimura, A
    [J]. NATURE, 1997, 387 (6636) : 921 - 924